Protocol summary

Study aim
Determining the effect of repeated letrozole dose on mature follicle and pregnancy rate in women with polycystic ovary syndrome resistant to the initial dose.
Design
A clinical trial with a control group with parallel, single-blind, randomized, phase 3, on 124 patients with polycystic ovary syndrome resistant to the initial dose of letrozole. The sealed envelope site was used for randomization.
Settings and conduct
Infertile women with polycystic ovary syndrome, referring to one of the private clinics in Rasht, who will be treated with letrozole in a dose of 5 mg/for 5 days. Then, on day 13-14 of the cycle, they will undergo transvaginal sonography, and if all follicles are less than 12 mm, they will be considered as not responding to letrozole.all these patients (resistant to the initial dose of letrozole) were randomly selected .They will be assigned to two intervention and control groups.study is single blinded.
Participants/Inclusion and exclusion criteria
Inclusion criteria: All infertile women with polycystic ovary syndrome resistant to letrozole primary treatment , with full consent to participate in the study, under the age of 35, With the indication of using oral medicine (not received 6 cycles of ovulation induction medication) Exclusion criteria: Obstruction of the fallopian tubes, absence of a normal uterine cavity , ovarian cysts , metabolic diseases and any disease with a negative effect on ovulation, chronic heart, liver and kidney diseases, abnormal sperm analysis, using other ovulation induction drugs at the same time
Intervention groups
The intervention group, will take 2 letrozoles per day for 5 days from the 14th (with repeated letrozole dose) The control group:without receiving letrozole again
Main outcome variables
The size of mature follicle equal to 17 mm in ultrasound evaluation on day 22-23 of the cycle

General information

Reason for update
Acronym
Letrozole
IRCT registration information
IRCT registration number: IRCT20081007001306N12
Registration date: 2024-06-13, 1403/03/24
Registration timing: prospective

Last update: 2024-06-13, 1403/03/24
Update count: 0
Registration date
2024-06-13, 1403/03/24
Registrant information
Name
Ziba Zahiri
Name of organization / entity
Guilan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 13 1322 5624
Email address
drzibazahiri@gums.ac.ir
Recruitment status
recruiting
Funding source
Expected recruitment start date
2024-06-21, 1403/04/01
Expected recruitment end date
2025-06-22, 1404/04/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigating the effect of repeated Letrozole doses on mature follicles status and pregnancy rate in women with polycystic ovary syndrome resistant to the initial Dose: a randomized controlled trial.
Public title
The effect of Letrozole on pregnancy rate in women with polycystic ovary syndrome
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
All infertile women with polycystic ovary syndrome resistant to letrozole primary treatment With full consent to participate in the study Under the age of 35 There is an indication for the use of oral medication (not received 6 cycles of ovulation induction medication)
Exclusion criteria:
Obstruction of the fallopian tubes Absence of a healthy uterine cavity Ovarian cysts Metabolic diseases and any disease that has a negative effect on ovulation Chronic heart, liver and kidney diseases Abnormal sperm analysis Using other ovulation induction drugs at the same time
Age
To 35 years old
Gender
Female
Phase
3
Groups that have been masked
  • Investigator
  • Data analyser
Sample size
Target sample size: 124
Randomization (investigator's opinion)
Randomized
Randomization description
124 PCOS women resistant to initial dose of letrozole are divided into 2 groups of 62 people (intervention and control). Group 1 (control) is named A and group 2 (intervention) is named B. Random block classification is assigned to the research units based on the randomized list by the sealed envelope website. Then a table that has 31 rows called block and each block will have 4 parts and each part will be named with A and B will be considered In the next step, the numbers are placed in each house in order. After all the numbers have been placed in the blocks, the people who had numbers in house A will receive packages with code A, and the people who have numbers in house B will receive packages with code B. Concealment is done using a sealed envelope method that is given to a third person outside the research team..
Blinding (investigator's opinion)
Single blinded
Blinding description
The study is single blinded, the final ultrasound to evaluate the diameter of the follicle is performed by the main researcher (project manager) who is not aware of the grouping. Also, for data analysis, a statistician who is separate from the study process and is unaware of all the performed processes will be used.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
ethics committee of guilan university of medical sciences
Street address
Research vice-chancellorship Building, in front of 17-Shahrivar Hospital, Shahid Siadati St., Namjoo Ave., Rasht, Guilan, IRAN
City
Rasht
Province
Guilan
Postal code
4144654839
Approval date
2024-05-08, 1403/02/19
Ethics committee reference number
IR.GUMS.REC.1403.073

Health conditions studied

1

Description of health condition studied
Female infertility
ICD-10 code
N97
ICD-10 code description
Female infertility

Primary outcomes

1

Description
The size of mature follicle equal to 17 mm in sonographic evaluation
Timepoint
On day 22-23 of the cycle
Method of measurement
By transvaginal ultrasound

Secondary outcomes

1

Description
Biochemical pregnancy rate
Timepoint
2-3 weeks after seeing the mature follicle
Method of measurement
through laboratory measurement (BhCG level)

2

Description
Clinical pregnancy
Timepoint
in 6-7 weeks of pregnancy
Method of measurement
Observation of fetal heartbeat in sonographic evaluation

3

Description
Early pregnancy failure(Ioss of pregnancy products before week12)
Timepoint
Before week 12
Method of measurement
By transvaginal ultrasound

4

Description
Multiple pregnancy (seeing two or more gestational sacs and fetal heart rate in them
Timepoint
In 6-7 weeks of pregnancy
Method of measurement
By transvaginal ultrasound

5

Description
Ectopic pregnancy (implantation somewhere other than inside the uterine cavity)
Timepoint
In week 5-7
Method of measurement
By transvaginal ultrasound

6

Description
Side effects of letrozole include: bone pain, fatigue, nausea, night sweats, hot flashes, headache and dizziness
Timepoint
At any time during the study process
Method of measurement
It is checked by a questionnaire

Intervention groups

1

Description
Control group:Eligible infertile women with polycystic ovary syndrome, referring to one of the private clinics in Rasht, who will be treated with letrozole in a dose of 5 mg/for 5 days. Then, on day 13-14 of the cycle, they will undergo transvaginal sonography, and if all follicles are less than 12 mm, they will be considered as not responding to letrozole.The control group will undergo transvaginal sonography again on day 22-23 of the cycle without receiving letrozole again
Category
Treatment - Drugs

2

Description
Intervention group:Infertile women with polycystic ovary syndrome who are resistant to initial dose of letrozole, will take 2 letrozoles per day for 5 days from the 14th day of menstruation and will undergo transvaginal sonography 3-4 days later (days 22-23 of the cycle).
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Private office
Full name of responsible person
Dr. Ziba Zahiri Sorouri
Street address
Venus Building,140 St., Somayeh Blvd., Golsar, R1asht
City
Rasht
Province
Guilan
Postal code
4165763654
Phone
+98 13 3213 1414
Email
zibazahiri@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Dr. Ramyar Farzan
Street address
Research vice-chancellorship Building, in front of 17-Shahrivar Hospital, Shahid Siadati St., Namjoo Ave., Rasht, Guilan, IRAN
City
Rasht
Province
Guilan
Postal code
41446-66949
Phone
+98 13 3333 5821
Fax
+98 13 3333 6395
Email
ramyarfarzan@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Rasht University of Medical Sciences
Proportion provided by this source
50
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Dr. Ziba Zahiri Sorouri
Position
professor
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN
City
Rasht
Province
Guilan
Postal code
54839 -41446
Phone
+98 13 3336 9224
Fax
+98 13 3336 9224
Email
zibazahiri@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Dr. Ziba Zahiri Sorouri
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN
City
Rasht
Province
Guilan
Postal code
54839 -41446
Phone
+98 13 3336 9224
Email
drzibazahiri@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Dr.zibazahiri
Position
professor
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN
City
Rasht
Province
Guilan
Postal code
54839 -41446
Phone
+98 13 3336 9224
Fax
+98 13 3336 9224
Email
drzibazahiri@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...